Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of topical LUT014 gel for EGFR inhibitor-associated acneiform rash in metastatic colorectal cancer
MOH_2021-02-22_009775Phase 2Not yet recruiting
- Sponsor
- Lutris Pharma
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LUT014 in acneiform rash and metastatic colorectal adenocarcinoma (mCRC) (4 arms), sponsored by Lutris Pharma. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
LUT014
03
Conditions
acneiform rashmetastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on MOH_2021-02-22_009775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-22_009775.